Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Completed · Phase 4

Conditions studied: Transplant Complication, CMV

In brief

The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).

Key facts

Study ID

NCT06034925

Run by

Medical University of South Carolina

People needed

70

Starts

2023-11-06

Expected to finish

2025-08-30

Last updated by the study team

2026-04-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Kidney transplant recipient at study institution
• =7 days of transplant
• Received at least one dose of rATG induction or patient is D+/R- CMV serostatus

You may not qualify if…

• Age <18 years at time of transplant
• Recipient of pancreas, liver, heart, lung transplant
• Recipient of investigational, non-FDA approved medication

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.